Trulicity
Overview
- Drug Brand Name: Trulicity
- Active moiety or active ingredient: dulaglutide
- Application Number: BLA125469
Trulicity Record of Action
Trulicity was selected for Cost Review by the Board on May 20, 2024.
Relevant Information:
- Presentation of findings from the drugs referred to the Stakeholder Council
- Written comments concerning list of therapeutic alternatives (30 days)
- Comments concerning Board selection of prescription drug products for cost review
The 60 day comment period was posted on May 23, 2024 and comments were accepted until July 22, 2024.
Relevant Information:
Comments received on Trulicity during the 60 day comment period
The request for information for Trulicity was distributed/posted on 7/25/2024. For each prescription drug product under review, the Board may request the following information from: Manufacturer, Health Insurance Carrier, HMO, and MCO, Pharmacy Benefit Managers, and Wholesale Distributors.
Read the archived RFI notice
The draft Trulicity dossier was posted on 8/20/25 and comments were accepted through 9/4/2025.
Written Comments Received
- August 20, 2025 Trulicity Dossier
- Exhibit 1: Pricing History_REDACTED
- Exhibit 2: RFI Submissions (NON-PUBLIC--TRADE SECRET, CONFIDENTIAL, AND PROPRIETARY)
- Exhibit 3: Trulicity Therapeutic Alternative Pricing_REDACTED
- Exhibit 4: Trulicity Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics
- Exhibit 5
- Exhibit 5A: Trulicity Summary of Cost Effectiveness Analyses
- Exhibit 5B: Trulicity Summary of Comparative Effectiveness Research
- Exhibit 6
- Exhibit 6A: Written Comments (60-day COMAR 14.01.04.05C(2))
- Exhibit 6B: Written Comments (Request October 28, 2024)
The final Trulicty dossier was posted on 11/4/2025 for discussion at the 11/17/2025 Board Meeting.
Written Comments Received
- November 4, 2025 Trulicity Dossier
- Exhibit 1: Pricing History_REDACTED
- Exhibit 2: RFI Submissions (NON-PUBLIC--TRADE SECRET, CONFIDENTIAL, AND PROPRIETARY)
- Exhibit 3: Trulicity Therapeutic Alternative Pricing_REDACTED
- Exhibit 4:Trulicity Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics
- Exhibit 5
- Exhibit 5A: Trulicity Summary of Cost Effectiveness Analyses
- Exhibit 5B: Trulicity Summary of Comparative Effectiveness Research
- Exhibit 6
- Exhibit 6A: Written Comments (60-day COMAR 14.01.04.05C(2))
- Exhibit 6B: Written Comments (Request October 28, 2024)
- Exhibit 6C: Written Comments (Request September 4, 2025)
The Board made a preliminary determination on November 17, 2025 and this preliminary determination included:
Board Preliminary Determination